Title:
ANTI-TAA/ANTI-CD3 MULTISPECIFIC ANTIBODY
Document Type and Number:
WIPO Patent Application WO/2023/219121
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing an anti-TAA/anti-CD3 multispecific antibody that can be used in treatment of humans. In order to produce an anti-TAA/anti-CD3 multispecific antibody that targets various tumor associated antigens (TAAs), the inventors of the present invention used their company's protein structure information analysis techniques and known information regarding anti-CD3 scFv, and obtained 16 types of anti-CD3 scFv which have affinity to various CD3 and improved stability. Furthermore, a multispecific antibody combining a plurality of anti-TAA antibodies for TSPAN8, CD37, etc. was produced, and it was confirmed that the obtained multispecific antibody maintained various binding activity to CD3 and stability. Thus, the obtained 16 types of anti-CD3 scFv can be used in producing an anti-TAA/anti-CD3 multispecific antibody for an arbitrary TAA.
Inventors:
SOGA SHINJI (JP)
YAGI SHIGENORI (JP)
SATAKE YOSHIKI (JP)
HONDA TAKASHI (JP)
SATO MASAHITO (JP)
CHAEN TAKASHI (JP)
YAGI SHIGENORI (JP)
SATAKE YOSHIKI (JP)
HONDA TAKASHI (JP)
SATO MASAHITO (JP)
CHAEN TAKASHI (JP)
Application Number:
PCT/JP2023/017663
Publication Date:
November 16, 2023
Filing Date:
May 11, 2023
Export Citation:
Assignee:
ASTELLAS PHARMA INC (JP)
International Classes:
C12N15/13; A61K39/395; A61P35/00; C07K16/28; C07K16/30; C07K16/32; C07K16/46; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/62; C12N15/63; C12P21/02
Domestic Patent References:
| WO2016020065A1 | 2016-02-11 | |||
| WO2022224997A1 | 2022-10-27 |
Foreign References:
| JP2021506293A | 2021-02-22 | |||
| JP2020534034A | 2020-11-26 | |||
| JP2020504104A | 2020-02-06 | |||
| JP2009039122A | 2009-02-26 |
Other References:
MALIK HARBANI; BUELOW BEN; RANGASWAMY UDAYA; BALASUBRAMANI AARTI; BOUDREAU ANDREW; DANG KEVIN; DAVISON LAURA; FORCE ALDRED SHELLEY: "TNB-486, a Novel Fully Human Bispecific CD19 x CD3 Antibody That Kills CD19-Positive Tumor Cells with Minimal Cytokine Secretion", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 134, 13 November 2019 (2019-11-13), US , pages 4070, XP086675314, ISSN: 0006-4971, DOI: 10.1182/blood-2019-123226
Attorney, Agent or Firm:
YAMAMOTO, Osamu et al. (JP)
Download PDF: